MULTIFUNSOME TERMINATED
Anti-EGFR Monoclonal Antibody Conjugated Thermoresponsive Liposome for Triple Negative Breast Cancer Thermo-Chemotherapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MULTIFUNSOME project word cloud
Explore the words cloud of the MULTIFUNSOME project. It provides you a very rough idea of what is the project "MULTIFUNSOME" about.
Project "MULTIFUNSOME" data sheet
The following table provides information about the project.
| Coordinator |
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 195˙454 € |
| EC max contribution | 195˙454 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2015 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-09-01 to 2019-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE | UK (CAMBRIDGE) | coordinator | 195˙454.00 |
Map
Project objective
In Europe, breast cancer is by far the most important cause of cancer death among women. In particular, triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and associated with poorer prognosis than other breast cancer subtypes. MULTIFUNSOME proposes the use of an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody-conjugated thermoresponsive liposome to deliver simultaneously an anticancer drug and superparamagnetic iron oxide nanoparticles (SPIO) to TNBC cells for thermo-chemotherapy. We will investigate: 1) the effect of combining anti-EGFR targeting and magnetic hyperthermia (MH) on TNBC in such thermo-chemotherapy and 2) how chemical-physical properties of the SPIOs and liposomes influence the therapeutic activity of the formulation. By conjugating anti-EGFR monoclonal antibody to a liposomal delivery system for targeting, drug and SPIO internalization into EGFR overexpressing TNBC cells will be greatly enhanced. SPIO co-encapsulation in the drug nano-cargo will induce a thermal dose to the TNBC cells when an alternating magnetic field is applied. MH will make TNBC cells more sensitive to chemotherapy and trigger the release of drugs intracellularly by enhancing the lipid membrane permeability. As a result, the effectiveness of chemotherapy could be synergistically enhanced by the concurrent application of MH and chemotherapy. The core size of SPIO will serve as a design parameter that can be readily manipulated to maximize the heating efficient of the multicore SPIO so as to minimize the necessary iron oxide content and maximize the drug encapsulation efficiency. The fellowship program will include a comprehensive training which will help the fellow to develop a unique multidisciplinary expertise. Furthermore, the project will generate important knowledge, impacts and collaborations in the European Research Area and could potentially address the critical need for a more efficacious TNBC therapy.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIFUNSOME" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MULTIFUNSOME" are provided by the European Opendata Portal: CORDIS opendata.